Artificial Intelligence

TIME's honor for AI's creators reveals a hidden truth: the digital revolution's massive energy and hardware needs are supercharging the race for minerals.

Engineering giant Amentum will leverage advanced tech in a decade-long, multi-billion dollar effort to help nations combat nuclear and biological threats.

A new contract for its explainable AI in a pivotal Phase 3 trial shows NetraMark is helping Big Pharma de-risk its most expensive R&D phase.

Early results for INT230-6 show 50% fewer severe side effects, raising hopes for a treatment that could eliminate the toxic 'red devil' chemo.

Beyond services, Charles River is building an ecosystem. We look at how its incubator nurtures startups and secures its own future in advanced medicine.

New Phase 2 data shows Elicio's off-the-shelf therapy ELI-002 7P induces "antigen spreading," creating a personalized anti-tumor response.

Astellas Pharma's new deal with venture studio Autobahn Labs isn't just a partnership; it's a strategic overhaul of the R&D pipeline. Here's why.

The latest O-RAN PlugFest showcases major AI integration and a shift to live networks, but the path to widespread commercial adoption remains complex.

In the heart of oil country, a new boom is taking shape. New Era Energy & Digital is building a gigawatt-scale AI campus, but can it win the infrastructure race?

A tech-driven 'anti-CRO' and a clinical accelerator have joined forces. Can their integrated model finally fix the broken drug development pipeline?

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

Brink's new $750M share repurchase is more than a financial move; it’s a bold declaration that its digital transformation is generating serious cash.

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

A third-generation family takeover, backed by Canada's BDC, positions a 70-year-old firm to accelerate innovation in the competitive medical imaging market.

Beyond the ad break: How TripleLift's focus on creative formats, global retail media partnerships, and AI is disrupting the programmatic advertising landscape.

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

A once-failed class of weight-loss drugs is back with a new design. Corbus Pharma's early data suggests it may have solved the safety puzzle.

Brii Biosciences partners with OpenBench, using an AI platform where they only pay for results. Is this the future of de-risking pharmaceutical R&D?

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.